Donitriptan (; developmental code name F-11356) is a triptan drug which was investigated as an antimigraine agent but was never marketed. It acts as a selective serotonin 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptor agonist. The drug reached phase 2 clinical trials prior to the discontinuation of its development.
Donitriptan acts as a high-affinity, high-efficacy near-full agonist of the serotonin 5-HT<sub>1B</sub> (K<sub>i</sub> = 0.079âÂÂ0.40nM; = 94%) and 5-HT<sub>1D</sub> receptors (K<sub>i</sub> = 0.063âÂÂ0.50nM; = 97%), and is among the most potent of the triptan series of drugs. It is also notable and unique among most of the triptans in being a potent serotonin 5-HT<sub>2A</sub> receptor agonist ( = 7.9nM), albeit with about one or two orders of magnitude lower activational potency than at the serotonin 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors.
Donitriptan is a tryptamine derivative, a 5-substituted derivative of tryptamine and 5-methoxytryptamine, and an analogue of the psychedelic drugs dimethyltryptamine (DMT) and 5-MeO-DMT.
The predicted log P of donitriptan is 1.32 to 2.2.
Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.